|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously described a patient with BRAF V600E mutation in primary tumor and a new mutation (V600E+K601del) in the matched-lymph node metastases.
|
19169486 |
2008 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In thyroid cancer, the V600E mutation occurs with greater frequently in aggressive subtypes of PTC, and in individuals that present at advanced stages of disease with extra-thyroidal extension and/or lymph node metastases.
|
19356676 |
2009 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant correlation was observed between the expression of 2 lncRNAs (XLOC_051122 and XLOC_006074) and 1) lymph node metastasis (N stage) and 2) BRAF(V600E) mutation.
|
27459529 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was significantly associated with age (≥ 45 years), tumor size (>1 cm), extrathyroidal extension, and cervical lymph node metastases (P < 0.05).
|
22190222 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases.
|
29215399 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The percentage of BRAF(V600E) alleles (P = 0.014), tumor volume (P = 0.012), and lymph node metastasis (P = 0.008) predicted the disease outcome.
|
22508706 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was associated with male sex (P = 0.028), large tumor size, extrathyroidal extension, central and lateral lymph node metastasis, and advanced tumor stage (P<0.0001).
|
25337709 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
EphB3 expression was negatively associated with invasive depth (P = 0.016, r<sub>s</sub> = -0.213), lymph node metastasis (P = 0.000, r<sub>s</sub> = -0.490), and TNM stage (P = 0.000, r<sub>s</sub> = -0.390), and was positively associated with poor differentiation (P = 0.001, r<sub>s</sub> = 0.290), BRAF V600E mutation (P = 0.008, r<sub>s</sub> = 0.235), and longer overall survival (P < 0.001).
|
30535864 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation.
|
21803329 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).
|
30254191 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found significant association between BRAF (V600E) mutation and age (P < 0.0001), extrathyroidal invasion (P = 0.017), lymph node metastasis (P = 0.038) and TNM stage III/IV (P = 0.001).
|
27387551 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor size correlated significantly with multifocality, extrathyroidal extension, and lymph node metastasis (P = 0.003, P < 0.001 and P < 0.001, respectively), but the BRAF V600E mutation status was not associated with any of those features.
|
22500044 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAF(V600E) mutant group and wild group.
|
24228637 |
2013 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Increased EHD2 mRNA expression level was associated with extrathyroidal extension (p < 0.001), pT3-4 (p < 0.001), lymph node metastasis (p < 0.001), higher risk of recurrence (p < 0.001), and BRAF V600E (p < 0.001).
|
28358874 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant correlation with BRAF (V600E) mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis.
|
26951110 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR=2.39 (95%) CI 1.00-5.75, p=0.052].
|
24839220 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report a 65-year-old woman with anaplastic thyroid carcinoma (BRAF V600E mutation) who had lymph node metastases (pT4 N1b) treated by total thyroidectomy, postoperative radiotherapy, adjuvant chemotherapy (paclitaxel and pazopanib) and targeted therapy (vemurafenib).
|
26347145 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence of the BRAF V600E mutation was 53.4%, and the rate of occult central lymph node metastasis was 25.7%.
|
22930785 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
No significant differences were observed in either the occurrence or the allele percentage of V600E mutation between the 2 groups of PTCs with or without LNMs.
|
23533235 |
2013 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
By contrast, positive status of BRAF(V600E) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18).
|
26871894 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, BRAF(V600E) mutation was not correlated with any of the prognostic factors including age ≥45 years, male gender, tumor size ≥1cm, multifocality, extra-thyroidal extension, concurrent Hashimoto's thyroiditis, and lymph node metastasis neither in the univariate nor in the multivariate analysis.
|
21862261 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further, no significant correlation of V600E expression with clinicopathologic parameters of aggressiveness such as lymph node metastasis, peritumoral infiltration, or perithyroidal infiltration was found.
|
22592144 |
2012 |